Different LD of Ticagrelor for Antiplatelet Effect in Patients With Non-ST-segment Elevation ACS Undergoing PCI

This study is not yet open for participant recruitment.
Verified October 2013 by General Hospital of Chinese Armed Police Forces
Sponsor:
Information provided by (Responsible Party):
General Hospital of Chinese Armed Police Forces
ClinicalTrials.gov Identifier:
NCT01962428
First received: October 10, 2013
Last updated: October 25, 2013
Last verified: October 2013
  Purpose

It is designed to test the hypothesis that high loading dose(360mg) ticagrelor versus conventional loading dose(180mg) will result in a higher inhibition of platelet aggregation(IPA) without increasing the bleeding events.


Condition Intervention Phase
Non ST Segment Elevation Acute Coronary Syndrome
Drug: ticagrelor
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Randomized Trial of Different Loading Dose of Ticagrelor for Antiplatelet Effect in Patients With Non -ST-segment Elevation ACS Undergoing Percutaneous Coronary Intervention

Resource links provided by NLM:


Further study details as provided by General Hospital of Chinese Armed Police Forces:

Primary Outcome Measures:
  • platelet reactivity index(PRI) measured by VASP-P [ Time Frame: 2 hours after the loading dose of ticagrelor ] [ Designated as safety issue: Yes ]
    Vasodilator-stimulated phosphoprotein(VASP) phosphorylation, a measure of P2Y12 receptor reactivity, was determined by flow cytometry with the use of the Platelet VASP-FCM Kit (Stago, France)and recorded as the platelet reactivity index (PRI).


Secondary Outcome Measures:
  • platelet reactivity index (PRI) measured by VASP-P [ Time Frame: 0.5hour,1hour,4hours,8hours,24hours after the loading dose of ticagrelor ] [ Designated as safety issue: Yes ]
  • bleeding events [ Time Frame: follow-up for 1 month ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 242
Study Start Date: December 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: high loading dose of ticagrelor
Patients will receive ticagrelor 360mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
Drug: ticagrelor
Other Name: Brilinta
Active Comparator: conventional loading dose of ticagrelor
Patients will receive ticagrelor 180mg loading dose, then 90mg bid maintenance dose starting 12 hours after loading dose.
Drug: ticagrelor
Other Name: Brilinta

Detailed Description:

After providing written informed consent, all patients will be randomized to receive ticagrelor 360mg or 180mg loading dose(LD),then 90mg bid maintenance dose starting 12 hours after LD.PCI will performed in 12h-24h after they are given the loading dose.All patients should receive acetylsalicylic acid (ASA) 75 to 100 mg daily unless intolerant.IPA at 0, 0.5, 1, 2, 4, 8, 24h after the loading dose of ticagrelor will be measured. CK-MB, troponin I, myoglobin, CRP will be detected at 0h, before PCI, 8h after PCI, 24h after PCI. ECG will be conducted at 0h, 8h and 24h after PCI. Patients returned 1 month for follow-up visits, documented any adverse events.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures.
  • Male or non-pregnant female; aged from 18 to 80 years old.
  • Patients with non-ST-segment elevation acute coronary syndromes who were scheduled to undergoing PCI.

Exclusion Criteria:

  • Any contraindication against the use of ticagrelor.
  • On treatment with a P2Y12 receptor antagonist in past 30 days.
  • Known allergies to aspirin or ticagrelor.
  • On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban).
  • Known blood dyscrasia or bleeding diathesis.
  • ST-segment elevation acute myocardial infarction.
  • Non-ST segment elevation acute coronary syndrome with high-risk features warranting emergency coronary angiography.
  • Left ventricular ejection fraction ≤30%; renal failure with creatinine 3 mg/dl; history of liver disease; an increased risk of bradycardia, and concomitant therapy with drugs interfering with CYP3A4 metabolism.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01962428

Contacts
Contact: Huiliang Liu, Doctor 86-10-57976531 lhl518@vip.sina.com
Contact: Yujie Wei, Doctor 86-10-57976707

Locations
China, Beijing
General Hospital of Chinese People's Armed Police Forces Not yet recruiting
Beijing, Beijing, China, 100039
Contact: Huiliang Liu, Doctor    86-10-57976531    lhl518@vip.sina.com   
Contact: Yujie Wei, Doctor    86-10-57976707      
Principal Investigator: Meihong Cui, Master         
Sponsors and Collaborators
General Hospital of Chinese Armed Police Forces
Investigators
Principal Investigator: Huiliang Liu, Doctor Department of Cardiology of General Hospital of Chinese People's Armed Police Forces
  More Information

No publications provided

Responsible Party: General Hospital of Chinese Armed Police Forces
ClinicalTrials.gov Identifier: NCT01962428     History of Changes
Other Study ID Numbers: ISSBRIL0214
Study First Received: October 10, 2013
Last Updated: October 25, 2013
Health Authority: China: Food and Drug Administration

Keywords provided by General Hospital of Chinese Armed Police Forces:
ticagrelor
loading dose
non-ST-segment elevation acute coronary syndromes
percutaneous coronary intervention
the antiplatelet effects
bleeding events
major adverse cardiac events

Additional relevant MeSH terms:
Acute Coronary Syndrome
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Angina Pectoris
Vascular Diseases
Chest Pain
Pain
Signs and Symptoms
Ticagrelor
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on April 17, 2014